CLINICAL_TRIALS
trial_result
· 2011-07-22
Clinical Trial Update: Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal [Phase 4]
Summary
Phase 4 trial comparing aliskiren 300 mg to telmisartan 80 mg in hypertension, assessing efficacy and safety after one week of treatment withdrawal.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis | Conditions: Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2011-07-22